Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RS Medical’s flagship product, the RS‐4i Plus Sequential Stimulator with Intersperse technology, delivers interferential therapy for deep tissue pain relief and neuromuscular electrical stimulation for muscle rehabilitation. Clinical results show that after 30 days of treatment, approximately 84% of patients experienced pain relief; about 73% reported relief lasting more than two hours[1].
The company’s devices are prescription-grade and designed for at-home use to empower patients with severe or debilitating musculoskeletal conditions to self-manage their symptoms safely.
No pharmaceutical clinical pipeline; all products are commercial-stage medical devices.
Over its history since founding in 1990, the company has helped over 1.5 million US patients reduce pain and regain mobility[2].
Products include the RS‐4i Plus Sequential Stimulator, Pronex Cervical Traction device, and others focused on non-invasive electrotherapy solutions[4].
Devices are prescribed by physicians across the United States.
The company maintains a direct sales force marketing to healthcare professionals nationwide[3][4].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RS Medical.